Recombinant Human B7-2/CD86 His Tag Protein, CF

Catalog #: 9090-B2 Datasheet / COA / SDS

Catalog #	Availability	Size / Price	Qty
9090-B2-100
9090-B2-01M

Recombinant Human B7-2/CD86 His Tag Protein Bioactivity

1 Image

Product Details

Supplemental Products

Reviews

Summary Product Datasheets Carrier Free Data Images Reconstitution Calculator Background Related Research Areas

Recombinant Human B7-2/CD86 His Tag Protein, CF Summary

Product Specifications

Purity

>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.

Endotoxin Level

<0.10 EU per 1 μg of the protein by the LAL method.

Activity

Measured by its binding ability in a functional ELISA. When Recombinant Human B7-2/CD86 is coated at 0.5 µg/mL, Recombinant Human CTLA-4 Fc Chimera (Catalog # 7268-CT) binds with a typical ED₅₀ of 7-42 ng/mL.

Source

Human embryonic kidney cell, HEK293-derived human B7-2/CD86 protein
Leu26-Pro247, with a C-terminal 6-His tag

Accession #

NP_787058

N-terminal Sequence
Analysis

Leu26

Predicted Molecular Mass

26 kDa

SDS-PAGE

57-66 kDa, reducing conditions

Product Datasheets

9090-B2

Product Datasheet

COA

SDS

Carrier Free

What does CF mean?

CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.

What formulation is right for me?

In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.

9090-B2

Formulation	Lyophilized from a 0.2 μm filtered solution in PBS.
Reconstitution	Reconstitute at 500 μg/mL in PBS.
Shipping	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage:	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 °C as supplied. 1 month, 2 to 8 °C under sterile conditions after reconstitution. 3 months, -20 to -70 °C under sterile conditions after reconstitution.

Scientific Data

Bioactivity

View Larger

When Recombinant Human B7-2/CD86 (9090-B2) is coated at 0.5 µg/mL, Recombinant Human CTLA-4 Fc Chimera (Catalog # 7268-CT) binds with a typical ED₅₀ of 7-42 ng/mL.

Reconstitution Calculator

Background: B7-2/CD86

B7-2, also known as CD86, B70, and ETC-1, is a 60-100 kDa variably glycosylated protein in the B7 family. B7 family members are transmembrane cell surface molecules that play important roles in immune activation and the maintenance of immune tolerance (1, 2). Mature human B7-2 consists of a 224 amino acid (aa) extracellular domain (ECD) with two Ig-like domains, a 21 aa transmembrane segment, and a 61 aa cytoplasmic tail (3, 4). Within the ECD, human B7-2 shares 59% aa sequence identity with mouse and rat B7-2. Alternative splicing of human B7-2 generates additional isoforms that lack both Ig-like domains or a region that includes the transmembrane segment. B7-2 is highly expressed on activated antigen presenting cells (APC), e.g. B cells, dendritic cells, and monocytes (4-7), as well as on vascular endothelial cells (8). B7-2 and the closely related B7-1/CD80 exhibit overlapping but distinct functional properties. Their binding to CD28, which is constitutively expressed on T cells, enhances T cell receptor signaling and also provides TCR-independent co-stimulation (3-5, 7, 9-11). B7-1 and B7-2 additionally bind the CD28-related protein, CTLA-4, which is up-regulated and recruited to the immunological synapse (IS) at the onset of T cell activation (3-5, 7, 9, 10). CTLA-4 ligation inhibits the T cell response and supports regulatory T cell function (12). B7-2 is expressed earlier than B7-1 following APC activation (6), and both proteins bind with higher affinity to CTLA-4 than to CD28 (10). B7-2 promotes the stabilization of CD28 in the IS, while B7-1 is primarily responsible for promoting CTLA-4 recruitment and accumulation in the IS (13). The relative participation of B7-1 and B7-2 in T cell co-stimulation can also alter the Th1/Th2 bias of the immune response (14). Both B7-1 and B7-2 serve as cellular receptors for B species adenoviruses (15).

References

Greenwald, R.J. et al. (2005) Annu. Rev. Immunol. 23:515.
Bour-Jordan, H. et al. (2011) Immunol. Rev. 241:180.
Freeman, G.J. et al. (1993) Science 262:909.
Azuma, M. et al. (1993) Nature 366:76.
Freeman, G.J. et al. (1993) J. Exp. Med. 178:2185.
Lenschow, D.J. et al. (1993) Proc. Natl. Acad. Sci. USA 90:11054.
Hathcock, K.S. et al. (1993) Science 262:905.
Seino, K. et al. (1995) Int. Immunol. 7:1331.
Chen, C. et al. (1994) J. Immunol. 152:4929.
Lanier, L.L. et al. (1995) J. Immunol. 154:97.
Rudd, C.E. et al. (2009) Immunol. Rev. 229:12.
Wing, K. et al. (2011) Trends Immunol. 32:428.
Pentcheva-Hoang, T. et al. (2004) Immunity 21:401.
Kuchroo, V.K. et al. (1995) Cell 80:707.
Short, J.J. et al. (2006) Virus Res. 122:144.

Entrez Gene IDs

942 (Human); 12524 (Mouse); 56822 (Rat); 102147235 (Cynomolgus Monkey)

Alternate Names

Activation B7-2 antigen; B70; B7-2 antigen; B72; B7-2; B-lymphocyte activation antigen B7-2; BU63; CD28 antigen ligand 2; CD28LG2B7-2 antigen); CD86 antigen; CD86 molecule; CD86; CTLA-4 counter-receptor B7.2; FUN-1; LAB72; MGC34413; T-lymphocyte activation antigen CD86